Xu Yuanda, Kong Xuetao, Huang Weiqing, Liang Zijing, Huang Jinkun, Li Yimin, Zhang Nuofu, Liu Dan, Guo Wenwei, Mei Jiang
State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Department of Critical Care Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, P. R. China.
Department of Public Health, Guangzhou Medical University, Guangzhou, China.
Ann Med. 2024 Dec;56(1):2307504. doi: 10.1080/07853890.2024.2307504. Epub 2024 Mar 11.
Despite the widespread administration of coronavirus disease 2019 (COVID-19) vaccines, the impact on patients with asymptomatic to mild illness remains unclear. Here, we aimed to assess the efficacy of various vaccine doses and types on the duration of isolation duration and discharge rates, the viral shedding duration, and negative rates in asymptomatic to mild COVID-19 patients.
We included adult patients at the Fangcang isolation centres in Pazhou or Yongning between November and December 2022. We analysed data on basic demographics, admission details, laboratory indicators and vaccination information.
A total of 6560 infected patients were included (3584 from Pazhou and 2976 from Yongning). Of these, 90.6% received inactivated vaccines, 3.66% received recombinant SARS-CoV-2 spike protein subunit vaccines and 0.91% received adenovirus vaccines. Among the 6173 vaccinated individuals, 71.9% received a booster dose. By day 9, the isolation rate reached 50% among vaccinated patients. On day 7.5, the positive rate among vaccinated individuals reached 50%.
Full vaccination was effective, with heterologous vaccines showing greater efficacy than inactivated vaccines alone. However, there was no significant difference in the vaccine protective effect 12 months after vaccination.
尽管2019冠状病毒病（COVID-19）疫苗已广泛接种，但对无症状至轻症患者的影响仍不明确。在此，我们旨在评估不同剂量和类型的疫苗对无症状至轻症COVID-19患者的隔离时长、出院率、病毒 shedding 时长以及核酸转阴率的影响。
我们纳入了2022年11月至12月期间在琶洲或永宁方舱隔离中心的成年患者。我们分析了基本人口统计学、入院详情、实验室指标和疫苗接种信息的数据。
共纳入6560例感染患者（3584例来自琶洲，2976例来自永宁）。其中，90.6%接种了灭活疫苗，3.66%接种了重组新型冠状病毒刺突蛋白亚单位疫苗，0.91%接种了腺病毒疫苗。在6173名接种疫苗的个体中，71.9%接受了加强针。到第9天，接种疫苗患者的隔离率达到50%。在第7.5天，接种疫苗个体的核酸阳性率达到50%。
全程接种疫苗是有效的，异源疫苗显示出比单独使用灭活疫苗更高的效力。然而，接种疫苗12个月后疫苗保护效果没有显著差异。
